ASCO® Annual Meeting 2023

AI-Enabled Precision Medicine is Here: Leveraging insights derived from data to advance cancer care

Kate Sasser, PhD, Chief Scientific Officer (Tempus); Calvin Chao, MD, SVP of Medical Affairs (Tempus); Ezra Cohen, MD, Chief Medical Officer of Oncology (Tempus)

Homologous Recombination Deficiency (HRD) in Non-Small Cell Lung Cancer: Genomic Analysis Using an RNA-based HRD Algorithm

First Author Stephanie Thiede (Tempus)

Genetic Ancestry Associations with Somatic Mutations in a Real-World Cohort of Over 3,000 Prostate Cancer Patients

First Author Brooke Rhead (Tempus)

Associations Between Androgen-Directed Treatments and AR Mutational Landscapes in the Circulating Tumor DNA of a Real-World Metastatic Prostate Cancer Cohort

First Author Elisa Ledet (Tulane)

Characterizing the landscape of RING-type E3 ubiquitin transferase altered (RNF43 alt*)* colorectal cancer (CRC) and defining unique subsets with potential therapeutic vulnerabilities in microsatellite instability-high (MSI-H) CRC

First Author Abdul Rafeh Naqash (University of Oklahoma)

Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers

First Author Catherine Handy Marshall (Johns Hopkins)

Molecular diagnostic classification for cancers of unknown primary (CUP): post-testing diagnosis and treatment impact analysis from real-world claims data

First Author Zachary Rivers, (Tempus)

Real-world Response Endpoints in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy Across Real-World Datasets

First Author Brittany McKelvey (Friends of Cancer Research)

Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer

First Author Rachel Minne (University of Wisconsin)

Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status

First Author Charu Aggarwal (University of Pennsylvania)

Germline alterations in patients with lung cancer

First Author Ramaswamy Govindan (Washington University)

Effect of germline mutations shape somatic alteration landscapes in BRCA-associated cancers

First Author Ali Arafa (University of Minnesota)

Genomic landscapes of early-onset versus average-onset colorectal cancer populations

First Author Michael H. Storandt (Mayo Clinic)

Microsatellite instability high (MSI-H): A definitive predictive biomarker for immune checkpoint inhibitors (ICI) yet understudied in underrepresented minorities (URM) with gastrointestinal (GI) cancers

First Author Fiyinfolu Balogun (Memorial Sloan Kettering)

Racial and Genetic Ancestry Associations with Gene Expression Patterns in a Real-World Cohort of Colorectal Cancer Patients

First Author David Hein (University of Texas South Western)

The Tempus TIME Trials Portal Maximizes Clinical Trial Enrollment

First Author Amol Rao (MemorialCare)

Integrated clinical, pathologic, and genetic data in a racially diverse hereditary breast cancer cohort

First Author Kenna Noel Koehler

Pathway enrichment analysis in tumors with high mutation burdens and interferon-g signature expression: A pan cancer analysis

First Author Xuanyi Li (Vanderbilt)

Clinical outcomes among patients with advanced non-small cell lung cancer who received targeted therapy in a real-world setting

First Author Mo Yang (EMD Serono)

Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer

First Author Jordan Kardos (Gilead)

Time Savings from Integrating Discrete, Genomic Data Into the Electronic Health Record Using the Epic Aura Network

First Author Leo Posteraro (Tempus)

The Genomic Landscape of Adolescent and Young Adult (AYA) Malignancies using DNA and RNA-based Next Generation Sequencing

First Author Maryam Lustberg (Yale)

Exchanging Genomics Reports Between Pathology Labs and Medical Centers Using the Minimal Clinical Oncology Data Element (mCODE) FHIR Implementation Guide

First Author James Chen (Tempus)

FcεRIγ-negative NK cells are associated with improved outcomes in trastuzumab-treated patients

First Author Vincent Perez (Tempus)

Using Real-World Evidence to Evaluate Broad Panel vs. Sequential Single and Narrow Panel Sequencing in Members with Non-Small Cell Lung Cancer (NSCLC)

First Author Brooke Byrd (CVS Health)

Association of molecular profiles of head and neck squamous cell carcinoma with heterogeneity across racial/ethnic groups in the United States

First Author Mihir Bhayani (Rush)

Identification of a novel class of early exon ALK rearrangements across two pan tumor sequencing databases

First Author Eric Vail (Cedars-Sinai Medical Center)

Genomic characterization of vulvar squamous cell carcinoma to reveal differential gene expression based on clinical outcome

First Author Sameer Talwalkar (Norton Cancer Institute), Mary Gordinier (Norton Healthcare)

Patient characteristics, treatment patterns, and clinical outcomes among patients with de novo advanced or metastatic (stage IIIB–IV) non-small cell lung cancer in a real-world setting

First Author Mo Yang (EMD Serono)

Analysis on real-world chemotherapy outcomes in patients (pts) with tyrosine kinase inhibitor (TKI) resistant advanced EGFR-mutant non–small-cell lung cancer (NSCLC) in the United States

First Author Dina Oksen (Merck KGaA)

RNA sequencing to characterize pathways in EGFR-mutated non-small cell lung cancer

First Author Nicole Yun (Rush)

Next generation sequencing (NGS) testing for cancer patients at a safety NET hospital

First Author Rizvan Azimazade (Alameda Health System)

Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes

First Author Michael Glover (Stanford)

Association of tumor homologous recombination deficiency (HRD) score with immune checkpoint inhibitor benefit in metastatic clear cell renal cell carcinoma

First Author Claud Grigg (Levine Cancer Institute)